Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Operating Leases (2020 - 2022)

Arcus Biosciences (RCUS) has 3 years of Operating Leases data on record, last reported at $119.2 million in Q3 2022.

  • For Q3 2022, Operating Leases rose 130.55% year-over-year to $119.2 million; the TTM value through Sep 2022 reached $119.2 million, up 130.55%, while the annual FY2021 figure was $116.9 million, 666.82% up from the prior year.
  • Operating Leases reached $119.2 million in Q3 2022 per RCUS's latest filing, down from $121.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $121.3 million in Q2 2022 and bottomed at $14.7 million in Q1 2021.
  • Average Operating Leases over 3 years is $75.5 million, with a median of $83.3 million recorded in 2021.
  • The widest YoY moves for Operating Leases: up 680.74% in 2022, down 130.55% in 2022.
  • A 3-year view of Operating Leases shows it stood at $15.2 million in 2020, then skyrocketed by 666.82% to $116.9 million in 2021, then increased by 1.97% to $119.2 million in 2022.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $119.2 million in Q3 2022, $121.3 million in Q2 2022, and $114.8 million in Q1 2022.